ClinicaliQ Trial Snapshot
- Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma. — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06609239.
- Lunsekimig (SAR443765) Long-term Asthma Trial Summary.
- Long-term safety and effectiveness study of lunsekimig injection for adults with asthma over 96 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig. The study duration will be up to 100 weeks with a treatment duration being up to 96 weeks. Conditions: Asthma Interventions: Lunsekimig Lead Sponsor: Sanofi Planned Enrollment: 900 participants